19 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Gainers

  • Audentes Therapeutics, Inc. BOLD shares rose 106.8% to $59.15 during Tuesday's pre-market session. The market cap seems to be at $1.2 billion. The most recent rating by Citigroup, on December 03, is at Neutral, with a price target of $60.00.
  • Quorum Health, Inc. QHC stock rose 38.8% to $0.75. The market cap seems to be at $36.5 million.
  • ViewRay, Inc. VRAY stock surged 33.8% to $4.55. The market value of their outstanding shares is at $258.4 million. The most recent rating by Oppenheimer, on October 22, is at Outperform, with a price target of $7.00.
  • uniQure, Inc. QURE stock increased by 18.7% to $65.00. The market cap stands at $2.1 billion. The most recent rating by Goldman Sachs, on December 03, is at Buy, with a price target of $98.00.
  • Axsome Therapeutics, Inc. AXSM shares surged 16.2% to $46.05. The market cap stands at $830.6 million. The most recent rating by Guggenheim, on October 16, is at Buy, with a price target of $48.00.
  • Co-Diagnostics, Inc. CODX stock surged 13.7% to $1.16. The market cap stands at $16.6 million.
  • Onconova Therapeutics, Inc. ONTX stock surged 9.7% to $0.32. The market cap stands at $4.3 million.
  • electroCore, Inc. ECOR shares rose 6.7% to $1.60. The market cap seems to be at $46.7 million. According to the most recent rating by JMP Securities, on November 14, the current rating is at Market Perform.
  • Pluristem Therapeutics, Inc. PSTI stock rose 2.2% to $3.69. The market cap seems to be at $52.0 million.

 

Losers

  • ASLAN Pharmaceuticals, Inc. ASLN stock plummeted 43.6% to $2.93 during Tuesday's pre-market session. The market cap seems to be at $49.3 million. The most recent rating by H.C. Wainwright, on November 14, is at Buy, with a price target of $2.00.
  • Cara Therapeutics, Inc. CARA shares decreased by 18.1% to $21.20. The market value of their outstanding shares is at $968.9 million.
  • resTORbio, Inc. TORC stock decreased by 6.4% to $1.17. The market cap stands at $264.2 million. The most recent rating by Cantor Fitzgerald, on November 15, is at Neutral, with a price target of $3.00.
  • Clovis Oncology, Inc. CLVS stock fell 5.0% to $15.60. The market value of their outstanding shares is at $173.7 million. The most recent rating by Evercore ISI Group, on November 19, is at In-Line, with a price target of $8.00.
  • Arrowhead Pharmaceuticals, Inc. ARWR stock decreased by 4.0% to $60.80. The market value of their outstanding shares is at $3.8 billion. The most recent rating by Baird, on November 25, is at Outperform, with a price target of $70.00.
  • Ocugen, Inc. OCGN shares declined 3.2% to $0.41. The market value of their outstanding shares is at $19.7 million. The most recent rating by Chardan Capital, on November 27, is at Buy, with a price target of $2.00.
  • Akari Therapeutics, Inc. AKTX shares declined 2.8% to $2.10. The market cap seems to be at $43.2 million.
  • AstraZeneca, Inc. AZN shares plummeted 1.7% to $47.58. The market cap stands at $126.9 billion. The most recent rating by Cowen & Co., on December 02, is at Outperform, with a price target of $55.00.
  • Aldeyra Therapeutics, Inc. ALDX shares fell 1.6% to $7.37. The market cap seems to be at $151.7 million. The most recent rating by Cantor Fitzgerald, on October 22, is at Overweight, with a price target of $33.00.
  • Fresenius Medical Care, Inc. FMS shares plummeted 1.0% to $36.03. The market cap stands at $21.6 billion. According to the most recent rating by Redburn, on October 23, the current rating is at Neutral.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsMovers & ShakersPre-Market OutlookMarketsMoversTrading IdeasGeneralHealthcare Stocks Pre-Market MoversTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!